MediaPress Releases Archives Media Inquiries In the News Press Releases FEATURED PRESS RELEASE August 21, 2024Tris Pharma Initiates ALLEVIATE-1 and ALLEVIATE-2, Pivotal Phase 3 Trials Investigating Cebranopadol, a First-in-Class Compound with a Novel Mechanism of Action to Treat Pain September 3, 2024Findings Presented at PAINWeek 2024 Demonstrate Tris Pharma’s Investigational, First-in-Class Therapy Cebranopadol Provides Potent, Prolonged Pain Relief with Improved Safety Over Oxycodone August 6, 2024Tris Pharma Presents New Clinical Data Demonstrating Robust Safety and Efficacy of Investigational, First-in-Class Therapy Cebranopadol for Treatment of Pain July 30, 2024Tris Pharma to Present New Safety Data for First-In-Class Investigational Pain Therapy and Host Symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain June 12, 2024Cranbury Pharmaceuticals Receives U.S. FDA Approval for First Generic Version of Emflaza® Oral Suspension (deflazacort) for Duchenne Muscular Dystrophy
